Balance Sheet Insights: Voyager Therapeutics Inc (VYGR)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

In the latest session, Voyager Therapeutics Inc (NASDAQ: VYGR) closed at $7.74 down -3.01% from its previous closing price of $7.98. In other words, the price has decreased by -$3.01 from its previous closing price. On the day, 0.78 million shares were traded. VYGR stock price reached its highest trading level at $7.995 during the session, while it also had its lowest trading level at $7.7.

Ratios:

For a deeper understanding of Voyager Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.82 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.63. For the most recent quarter (mrq), Quick Ratio is recorded 4.96 and its Current Ratio is at 4.96. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on March 26, 2024, initiated with a Buy rating and assigned the stock a target price of $22.

On March 19, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.

On March 07, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $16.Citigroup initiated its Buy rating on March 07, 2024, with a $16 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 02 ’24 when Sandrock Alfred sold 12,115 shares for $9.86 per share. The transaction valued at 119,454 led to the insider holds 322,839 shares of the business.

Swartz Robin sold 1,357 shares of VYGR for $13,407 on Apr 02 ’24. The Chief Operating Officer now owns 117,004 shares after completing the transaction at $9.88 per share. On Feb 21 ’24, another insider, Sandrock Alfred, who serves as the President and CEO of the company, sold 13,033 shares for $7.46 each. As a result, the insider received 97,226 and left with 334,954 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 420286624 and an Enterprise Value of 209704848. As of this moment, Voyager’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.68 while its Price-to-Book (P/B) ratio in mrq is 1.44. Its current Enterprise Value per Revenue stands at 0.839 whereas that against EBITDA is 1.658.

Stock Price History:

The Beta on a monthly basis for VYGR is 0.98, which has changed by -0.025188923 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $14.34, while it has fallen to a 52-week low of $6.06. The 50-Day Moving Average of the stock is -11.50%, while the 200-Day Moving Average is calculated to be -7.16%.

Shares Statistics:

For the past three months, VYGR has traded an average of 631.75K shares per day and 496270 over the past ten days. A total of 54.30M shares are outstanding, with a floating share count of 44.42M. Insiders hold about 18.20% of the company’s shares, while institutions hold 48.35% stake in the company. Shares short for VYGR as of 1711584000 were 3330926 with a Short Ratio of 5.27, compared to 1709164800 on 2262316. Therefore, it implies a Short% of Shares Outstanding of 3330926 and a Short% of Float of 7.33.

Earnings Estimates

The stock of Voyager Therapeutics Inc (VYGR) is currently drawing attention from 9 analysts actively involved in the ongoing evaluation and rating process.On average, analysts expect EPS of -$0.44 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.52, while EPS last year was $2.94. The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.32 and low estimates of -$0.67.

Analysts are recommending an EPS of between -$0.6 and -$2.9 for the fiscal current year, implying an average EPS of -$1.8. EPS for the following year is -$1.73, with 9 analysts recommending between $0.15 and -$4.18.

Revenue Estimates

A total of 8 analysts believe the company’s revenue will be $9.41M this quarter.It ranges from a high estimate of $16M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $150.48M, an estimated decrease of -93.70% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $7.29M, an increase of 50.20% over than the figure of -$93.70% in the same quarter last year. There is a high estimate of $16M for the next quarter, whereas the lowest estimate is –$.

A total of 10 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $90.14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $38.84M. In the same quarter a year ago, actual revenue was $250.01M, down -84.50% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $54.1M in the next fiscal year. The high estimate is $154.92M and the low estimate is –$. The average revenue growth estimate for next year is up 39.30% from the average revenue estimate for this year.

Most Popular

[the_ad id="945"]